Kyntra Bio, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Drug Product Revenue at $5.8 million, 91% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5
|
6
|
30
|
47
|
141
|
235
|
176
|
257
|
213
|
131
|
183
|
| Product |
—
|
—
|
—
|
101
+21.8%
share 215.7%
|
83
+74.0%
share 58.9%
|
48
-34.3%
share 20.2%
|
72
+4164.6%
share 41.1%
|
2
-97.4%
share 0.7%
|
65
share 30.4%
|
—
|
—
|
| License |
—
|
—
|
—
|
10
-57.3%
share 20.6%
|
23
-80.6%
share 16.1%
|
116
+712.9%
share 49.5%
|
14
-91.9%
share 8.1%
|
177
+695.2%
share 69.0%
|
22
+124.2%
share 10.5%
|
10
share 7.6%
|
—
|
| Drug Product Revenue |
4
-36.9%
share 85.6%
|
6
-78.9%
share 90.8%
|
28
+47.6%
share 93.4%
|
19
+69.2%
share 40.1%
|
11
+1052.4%
share 7.9%
|
1
-89.2%
share 0.4%
|
9
+124.5%
share 5.1%
|
-36
-156.1%
share -14.2%
|
65
share 30.4%
|
—
|
—
|
| Drug Product |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2
share 0.7%
|
—
|
—
|
—
|
| Development And Other Revenue |
1
-38.4%
share 14.4%
|
1
-69.6%
share 9.2%
|
2
-89.4%
share 6.6%
|
18
-23.9%
share 39.3%
|
24
-65.6%
share 17.2%
|
70
-12.8%
share 29.9%
|
81
-29.4%
share 45.7%
|
114
-9.4%
share 44.5%
|
126
+4.0%
share 59.1%
|
121
share 92.4%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KYNB (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 921299
- Former names
- FIBROGEN INC (until Jan 7, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.